Dimerix (ASX: DXB) — Company Overview, News & Financial Data
Dimerix is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for inflammatory diseases, with a primary focus on rare kidney and respiratory conditions.
Dimerix
Dimerix is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for inflammatory diseases, with a primary focus on rare kidney and respiratory conditions. Based in Fitzroy, Victoria, the company utilizes proprietary drug discovery technology to target G-protein coupled receptor interactions involved in disease pathology. Its principal late-stage clinical candidate is undergoing global Phase 3 trials for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder causing progressive renal failure. Additional clinical and preclinical development programs target diabetic kidney disease, acute kidney injury, and chronic obstructive pulmonary disease.
Snapshot
Operations
Products and/or services of Dimerix
- Focal Segmental Glomerulosclerosis Therapeutics: Phase 3 clinical development of an oral chemokine receptor CCR2 antagonist administered alongside standard-of-care angiotensin II receptor blockers to reduce proteinuria and preserve kidney function in patients diagnosed with rare inflammatory kidney disorders.
- Diabetic Kidney Disease Therapies: Phase 2 clinical evaluation investigating dual-targeted receptor inhibition therapy designed to address kidney inflammation and progressive renal function decline in adult patients suffering from diabetic nephropathy receiving stable background treatment regimens.
- Chronic Obstructive Pulmonary Disease Therapies: Preclinical and early-stage clinical research evaluating small-molecule candidates targeting G-protein coupled receptor complexes to suppress lung inflammation and tissue damage in patients experiencing chronic obstructive pulmonary disease and related respiratory conditions.
- Acute Kidney Injury Therapeutics: Preclinical formulation and development of targeted anti-inflammatory molecules aimed at preventing cellular injury and preserving organ tissue integrity in patients suffering from acute kidney injury during critical medical complications.
- Drug Discovery Platform: Proprietary assay technologies designed to identify and characterize G-protein coupled receptor heteromer interactions, enabling functional screening and rational design of novel pharmaceutical compounds targeting complex inflammatory signaling pathways across disease indications.
Dimerix executive team
- Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D.CEO, MD & Director
- Mr. Robert ShepherdChief Operating Officer
- Dr. David Everett Fuller BPharm, M.D., MBBSChief Medical Officer
- Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D.CFO & Company Secretary
- Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.Chief Scientific Advisor